Methods of inhibiting ECM accumulation in the CNS by inhibition of TGF-.beta.
US5958411A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Mar 24, 1995 |
| Grant date | Sep 28, 1999 |
| Priority date | — |
| Expiry date | Mar 24, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/1841
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods for preventing, suppressing or treating a CNS pathology characterized by a deleterious accumulation of extracellular matrix in a tissue by contacting the tissue with an agent that inhibits the extracellular matrix producing activity of TGF-.beta.. The methods can be used to prevent, suppress or treat scar formation in the CNS. Agents that are useful in the present methods include neutralizing anti-TGF-.beta. antibodies, Arg-Gly-Asp-containing peptides, decorin and its functional equivalents such as biglycan, and TGF-.beta. antagonists. The present invention further provides methods for preventing, suppressing or treating a CNS pathology characterized by the insufficient accumulation of extracellular matrix. Agents that enhance the production of extracellular matrix, such as TGF-.beta., can be used in such methods. Finally, the present invention provides pharmaceutical compositions containing these agents, which can be administered to patients to inhibit or enhance the production of extracellular matrix in the CNS.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.